OREANDA-NEWS. January 25, 2012. FAS Commission found that the Ministry of Health Care and Social Development of the Russian Federation unreasonably refused to grant permits to “BIOCAD” CJSC to import “Imatinib” and “Anastrozole” non-registered medicines in violation of Part 1 Article 15 of the Federal Law “On Protection of Competition”, reported the press-centre of FAS Russia.

The Ministry of Health Care and Social Development violated the five-day period for considering petitions of “BIOCAD” CJSC.

Such actions of the Ministry of Health Care and Social Development could have increased the periods of launching new generic drugs on the Russian market.

“The FAS determination is designed to stop violations of the antimonopoly law with regard to the economic entities that apply to the Ministry of Health Care and Social Development for the permits to import non-registered medicines to the Russian Federation”, pointed out the Head of FAS Department for Control over Social Sphere and Trade, Timophei Nizhegorodtsev.